Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12094240 | 0.82 | ALDH1A1 (0.48) | TP53AKT1DRD2LMNAMAPT | |
| SCHEMBL12697308 | 0.79 | MTNR1A (0.56) | TP53KDM4ELMNAMAPTMGLL | |
| SCHEMBL19698118 | 0.78 | OPRM1 (0.47) | TP53AKT1DRD2LMNAMAPT | |
| SCHEMBL998261 | 0.78 | AKT1 (0.59) | AKT1DRD2ALDH1A1 | |
| SCHEMBL16096215 | 0.77 | PTGS1 (0.48) | TP53AKT1DRD2LMNAMAPT | |
| SCHEMBL22915372 | 0.77 | AKT1 (0.41) | TP53AKT1DRD2LMNAMAPT | |
| SCHEMBL24726775 | 0.76 | AKT1 (0.45) | TP53AKT1LMNAMAPTMGLL | |
| SCHEMBL15235369 | 0.76 | MTNR1A (0.53) | TP53LMNAMAPTMGLLFAAH | |
| SCHEMBL20246935 | 0.76 | MGLL (0.46) | TP53AKT1DRD2LMNAMAPT | |
| SCHEMBL9737672 | 0.76 | MGLL (0.46) | TP53AKT1DRD2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857636-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ALFASIGMA S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-10967069-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-04-06 | — | — | US | disclosed |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-20190247513-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-08-15 | — | — | US | disclosed |
| US-10376594-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-08-13 | — | — | US | disclosed |
| US-10004810-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-9931408-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2018-04-03 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-10967069-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-20190247513-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | TP53 1269/4885KDM4E 2186/4885AKT1 4301/4885 |
| US-20210128740-A1 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | ERBB3, HDAC6, ERBB2 | TP53 1639/4885KDM4E 627/4885AKT1 600/4885 |
| US-20190336612-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | TP53 1354/4885KDM4E 2183/4885AKT1 4265/4885 |
| US-11857636-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-10004810-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
| US-10376594-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | TP53 1641/4885KDM4E 1403/4885AKT1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.